The latest clinical result of SNS-101(Sensei Biotherapeutics) in patients with advanced solid tumors was reported at the 2023 SITC Congress, demenstrating its potential efficacy and paving the way for future research.
COX-2 inhibitors aid in the release of prostaglandins, which are synthesized from arachidonic acid. Prostaglandins play a key role in inflammatory responses.
Open reading frame (ORF), in the context of genomics, refers to a section of a DNA sequence that lacks a stop codon and potentially codes for a protein.
This article summarized the latest R&D progress of Umeclidinium Bromide, the Mechanism of Action for Umeclidinium Bromide, and the drug target R&D trends for Umeclidinium Bromide.
Alvotech, a global biotech firm specializing in biosimilar drugs, and Canada's JAMP Pharma have announced Health Canada's approval for AVT04, a Stelara® biosimilar. It will be marketed as Jamteki™.
The 2023 SITC Congress kicked off with a groundbreaking report on the latest clinical results of ENB-003, establishing a solid foundation for future research.
On Oct 31, 2023, the latest clinical data of MDNA11 monotherapy in a phase 1/2 study on advanced solid tumors was reported at SITC Congress, showing potential efficacy for future research.
Latest news on PACIFIC-2 Phase III study of Imfinzi given along with platinum-based chemo and radiotherapy for Stage III non-small cell lung cancer that can't be surgically removed.